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Since their discovery as a tool for gene transfer, vectors derived from the adeno-associated
virus (AAV) have been used for gene therapy applications and attracted scientist to this
field for their exceptional properties of efficiency of in vivo gene transfer and the level
and duration of transgene expression. For many years, AAVs have been considered as
low immunogenic vectors due to their ability to induce long-term expression of non-self-
proteins in contrast to what has been observed with other viral vectors, such as adenovirus,
for which strong immune responses against the same transgene products were docu-
mented.The perceived low immunogenicity likely explains why the use of AAV vectors for
vaccination was not seriously considered before the early 2000s. Indeed, while analyses
conducted using a variety of transgenes and animal species slowly changed the vision of
immunological properties of AAVs, an increasing number of studies were also performed
in the field of vaccination. Even if the comparison with other modes of vaccination was not
systemically performed, the analyses conducted so far in the field of active immunother-
apy strongly suggest that AAVs possess some interesting features to be used as tools
to produce an efficient and sustained antibody response. In addition, recent studies also
highlighted the potential of AAVs for passive immunotherapy. This review summarizes the
main studies conducted to evaluate the potential of AAV vectors for vaccination against
infectious agents and discusses their advantages and drawbacks. Altogether, the variety
of studies conducted in this field contributes to the understanding of the immunological
properties of this versatile virus and to the definition of its possible future applications.
Keywords: AAV vectors, anti-viral vaccination, humoral responses, cytotoxic responses, antibody gene transfer,
immunoadhesins, capsid
INTRODUCTION
Historically, vaccination strategies against infectious agents have
mostly used live attenuated pathogens. These vaccines are highly
efficient for generating both humoral and cellular immune
responses but for many pathogens this approach is too risky
even in their attenuated form to be used in humans. Subunit
vaccines, usually recombinant proteins, have provided an inter-
esting and safe alternative; however their use is limited to the
generation of antibody (Ab) responses and is, therefore, limited
to preventive vaccination strategies against pathogens that can be
efficiently cleared by a humoral response. In addition, their effi-
ciency frequently requires repeated injections of high doses of the
vaccines coupled to adjuvants. In this context, the development of
viral vector has provided a very interesting alternative since they
can efficiently deliver antigens (Ag) into the antigen processing
pathway leading to the stimulation of cytotoxic T cell responses,
which are essential to clear intra-cellular pathogens and to develop
therapeutic vaccines (1).
Viral vectors are derived from wild type viruses by deleting
a part or all of viral genes. The immunogenic properties of a
viral vector results not only from that of Ag which is expressed,
but also on the intrinsic biological properties of the viral particle
which determine its interaction with the cells of the immune sys-
tem, in particular antigen presenting cells (APC), and with other
target tissues. Both contribute to the nature and the potency of the
immune response that is induced (1). So far, the most widely eval-
uated viral vectors for vaccination, in particular, in human clinical
trials are those derived from adenovirus (Ad) and the poxvirus
family (2). Both of these types of vectors provide several advan-
tages as vaccines because of their efficiency of infection of several
cell types including APC. However, when used as a vaccine both
types of vectors contain, in addition to the transgene encoding for
the Ag, several viral genes whose expression can constitute a safety
concern and lower or modify the efficacy of the vaccine by divert-
ing immune responses from the Ag itself. In addition, for both
vector types, if the strong immunogenicity of the viral particle
itself may be seen as helping to induce strong immune responses,
it can also constitute a safety problem, due to the strong inflam-
matory responses that are induced. Last but not least, as for many
other viral vectors, a main issue is that of the pre-existing immu-
nity in the human population, which may constitute a barrier to
their use in man.
Adeno-associated virus (AAV) vectors already have a relatively
long history in gene therapy but have only recently emerged in
the vaccination field. Since the first and unique report by Man-
ning et al. (3) documenting the capacity of AAV to induce a strong
humoral and cellular response against the herpes simplex virus
(HSV) type 1 glycoprotein B (3), an increasing number of studies
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have explored the use of AAV vectors for genetic vaccination, thus
contributing to the understanding of their immunological proper-
ties. This review is focused on the description of vaccination stud-
ies conducted mostly against viral or microbial antigens and using
AAV vectors directly in vivo to highlight their properties, poten-
tial limitations, and future developments. Neither the few studies
which used AAV vectors for vaccination against non-infectious
diseases nor the use of these vectors for immunotherapy by ex vivo
gene transfer into dendritic cells (DC) are included. The two first
sections summarize the main characteristics of AAV vectors when
used in various vaccination settings. The third section presents the
results from the most advanced studies, which explored the poten-
tial of AAV vaccines against experimental challenge in a relevant
animal model and/or have explored the efficacy of AAV-mediated
vaccination in non-human primates (NHP). Finally, the last part
of this review describes the most likely future developments in this
field.
AAV VECTORS FOR ACTIVE IMMUNOTHERAPY
Compared to other viruses used as vectors for vaccination and in
particular to Ad and poxviruses, AAV potentially offers a signif-
icant number of advantages. First, the vectors are derived from
a non-pathogenic virus that is inherently replication defective
(4). Accordingly, several preclinical and clinical gene therapy tri-
als have demonstrated their favorable safety profile (5, 6). The
vectors are gutless and, therefore do no encode for any viral
gene. The vector genome is usually composed of a single-stranded
(ss) DNA molecule containing the transgene expression cassette
flanked by the viral inverted terminal repeats [for a review, see
Ref. (7)]. AAV particles containing a double-stranded, also called
self-complementary (sc) AAV genome, can be also developed to
improve the kinetics and the level of expression of the transgene
(8). AAV vectors possess the capacity to efficiently transduce sev-
eral tissues in vivo and the isolation of several AAV serotypes and
of a multitude of capsid variants potentially offers the possibility to
develop prime/boost strategies by switching the AAV capsid, thus
avoiding the anti-capsid neutralizing humoral responses induced
after the first injection. However, as with other viral vector sys-
tems, AAVs also have a number of drawbacks, notably the limited
transgene capacity, a strong and wide pre-existing immunity in
humans, and the technological challenge of producing large and
high titter vector stocks. The studies conducted in the field of active
vaccination using AAV vectors are very diverse in terms of targets,
objectives, and strategies (Table 1). However, so far, only a limited
number of studies have been conducted directly comparing AAV
vectors to other vector vaccines. Despite this diversity and lack of
comparative studies, several common conclusions can be extrap-
olated from these studies which define the advantages and also the
pitfalls of AAV vectors for this particular application.
EVALUATION OF DIFFERENT AAV SEROTYPES AND ROUTES OF
IMMUNIZATION
Initial analyses conducted in the field of vaccination have been per-
formed using AAV2-derived vectors. Despite their lower efficiency
compared to other AAV serotypes (29), in these initial studies,
AAV2 vectors already demonstrated their capacity to induce strong
immune responses using a variety of injection routes and viral Ag
Table 1 | Summary of active immunization studies using AAV vectors.
Antigen AAV serotype Injection route Reference
HSV-1
(gB and gD)
AAV2 IM/mice Manning et al. (3)
HPV (E7, E7/
hsp70 L1)
AAV2 IM/mice Liu et al. (9)
AAV2 IM/mice Liu et al. (10)
AAV5 IN/mice Kuck et al. (11)
AAV5, 8, 9 IN/mice Nieto et al. (12)
AAV1, 2 IM/mice Zhou et al. (13)
AAV5, 9 IN/macaques Nieto et al. (14)
HIV
(env, tat, rev)
AAV2 IM, SC, IN,
IP/mice
Xin et al. (15)
AAV2 Oral/mice Xin et al. (16)
AAV1, 3, 4, 5, 7, 8 IM/mice Xin et al. (17)
AAV1, 2, 5, 7, 8, 9 IM/mice Lin et al. (18), Lin
et al. (19)
AAV8, rh32-33 IM/mice Lin et al. (20)
scAAV2, 7, 8 IM/mice Wu et al. (21)
SIV AAV2 IM/macaque Johnson et al. (22)
SARS-CoV
(S protein)
AAV2 IM/mice Du et al. (23)
Malaria
(MSP4, 4/5)
AAV1, 3 IM/mice Logan et al. (24)
Influenza (NP,
H1, M1)
AAV8, rh32.33 IM/mice Lin et al. (20)
AAV9 IM/mice Sipo et al. (25)
DEV (Env) AAV8, rh32.33 IM/mice Li et al. (26)
TB (Ag85A) Modified AAV2 IM/mice Rybniker et al. (27)
NIV (G protein) AAV1, 8, rh32.33 IM, ID/mice Ploquin et al. (28)
IM, intra-muscular; IN, intra-nasal; ID, intra-dermal; IP, intra-portal; IPL, intra-
pleural; HSV-1, herpes simplex virus type 1; HPV, human papillomavirus; HIV,
human immunodeficiency virus; SIV, simian immunodeficiency virus; SARS-
CoV, severe acquired respiratory syndrome coronavirus; DEV, dengue virus; TB,
Mycobacterium tuberculosis, NIV, Nipah virus.
derived from HSV, the human immunodeficiency virus (HIV),
the severe acquired respiratory syndrome coronavirus (SARS-
CoV), and the human papillomavirus (HPV) (3, 10, 15, 16, 30)
(Table 1). Notably, a study using AAV2 vectors expressing several
simian immunodeficiency virus (SIV) genes indicated that a single
intra-muscular administration of the vector was able to elicit SIV-
specific T cells and Ab, demonstrating its potential in a macaque
NHP model (22). Thereafter, other AAV serotypes rapidly entered
the field and out-performed AAV2 in terms of immune responses,
as expected from their higher efficiency for gene transfer (13, 17–
19, 28). The use of various AAV serotypes also allowed varying
the injection routes (Table 1). In particular, several studies have
used AAV5 or AAV9 vectors for intra-nasal vaccination to induce
a mucosal immunity (11, 12). Most notably, nasal application of
AAV9 was efficient even in the presence of high levels of pre-
existing serum anti-AAV9 neutralizing antibodies (NAb), which
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did not prevent re-immunization with the same serotype and
transgene expression (14, 31).
INDUCTION OF HUMORAL RESPONSES
A remarkable feature of AAV vector vaccines in most, if not all
studies, is their capacity to induce strong and long lasting Ab
responses, even after a single administration. Several studies doc-
umented the induction of humoral responses lasting for many
months and sometimes more than 1 year (3, 11, 12, 26, 28). In addi-
tion, in some studies, the AAV-induced Ab response was higher and
more sustained than using other vaccination strategies including
DNA, recombinant proteins, inactivated virus, or virus-like parti-
cles (VLPs) (3, 10–12, 24, 30). Such pronounced Ab response may
be linked to the high and sustained expression of the transgene
over time achieved with most AAV serotypes (18, 19, 26, 28). The
high and long lasting level of Ab responses may also explain why,
in some instances, a boost effect was not always observed upon
re-injection with the same or an alternative AAV serotype (22, 24,
28). In contrast, some studies have documented the possibility
of enhancing the AAV-induced humoral response by using an Ad
vector expressing the same Ag for the boost (18, 19). These obser-
vations suggest that the enhancement of humoral responses can
be achieved only after stimulation of different immune pathways
than those used for the initial prime vaccination. This scenario is
similar to that described for vaccination strategies using plasmid
DNA for the prime injection and an heterologous vaccine for the
boost (1).
INDUCTION OF CD8+ T-CELL RESPONSES
The control of several infectious diseases requires, in addition to
a strong humoral response, the concomitant induction of cyto-
toxic cellular responses to not only prevent virus spreading but
also eradicate virus-infected cells. Since the first report using AAV
for vaccination, several studies have documented the induction
of transgene-specific CD8+ T-cell responses following injection
of AAV vectors in mice (3, 12, 13, 15, 17, 25) and NHP (22).
However, only two studies have thoroughly analyzed such cellular
responses quantitatively and qualitatively. Two reports, published
in 2007 indicated that CD8+ T-cell responses induced by AAV
vectors, derived from a variety of natural AAV serotypes, failed to
be successfully recalled and amplified upon a boost with an Ad
vector indicating a default in the CD8+ T-cell memory response.
A detailed analyses of such responses further showed that CD8+
T cells had markers of exhaustion, which were correlated to a
continuous expression of the transgene (18, 19). Whether the per-
sistence of transgene expression was a consequence or a cause of
such a functionally impaired CD8+ T-cell response is still unclear.
Interestingly however, a functional transgene-specific CD8+ T-cell
response could be induced by changing the AAV capsid. A hybrid
capsid AAVrh32.33, derived from two natural rhesus macaque iso-
lates, was able to generate a CD8+ T-cell response against the
transgene product in mice and NHP which could be successfully
amplified following a boost with an Ad vector (20). Further studies
conducted in mice demonstrated that intra-muscular administra-
tion of the AAVrh32.33 vector was able to induce a strong cellular
response even against transgene products, such as LacZ, which
are usually tolerated using natural AAV serotypes and resulted
in the elimination of AAV-transduced cells within 2 months after
AAV administration (32). Altogether, these analyses indicated that
the capsid, in addition to the transgene, is a key modulator of
immune responses in particular by changing the tropism, and thus
the interaction of AAV particles with immune cells. It is worth
noting that although natural AAV serotypes are considered to be
unable to efficiently transduce APC, in particular DC, it is currently
unknown how AAVrh32.33 interacts with these cells. Finally, it is
important to highlight that such strong differences among AAV
capsids, observed in murine models may not hold true in other
animals species, in particular primates, in which even natural AAV
vectors were shown to induce immune responses leading to the
elimination of transgene-expressing cells (33).
AAV VECTORS FOR PASSIVE IMMUNOTHERAPY
The ability of AAV vectors to efficiently express various transgenes
including those coding for soluble proteins has fostered their use
for Ab-gene transfer to produce neutralizing Ab (NAb) directly
in vivo (Table 2). Indeed, Ab-based therapies are costly and lim-
ited by the half-life of the Ab, with single administrations resulting
only in short term protection. Therefore, most of these therapies
require frequent administration of relatively high doses of the Ab,
often via intravenous administration, since high and persistent
serum levels of Ab are frequently required for optimal clinical
efficacy. In this scenario, the use of AAV vectors may be of great
interest, in particular, to allow a sustained and continuous expres-
sion of the Ab after a single administration. In these studies, as in
gene therapy,AAV vectors are used only as vehicles to produce high
levels of proteins in vivo and, in contrast to the previous situation
(active immunotherapy), immune responses against the transgene
product, here the Ab, are unwanted. Most of the studies performed
in this area are recent and have used natural AAV serotypes other
than AAV2 (Table 2).
One of the challenges in the engineering of an AAV vec-
tor coding for a full length Ab was to ensure an efficient and
equimolar production of the light and heavy chains. A major
advance was achieved by demonstrating the possibility to pro-
duce high levels of Ab in mice after intra-portal administration of
an AAV8 vector expressing heavy and light chains linked with a
Table 2 | Summary of passive immunization studies using AAV
vectors.
Antigen AAV serotype Injection route Reference
HIV AAV2 IM/mice Lewis et al. (34)
AAV8 Balazs et al. (35)
RSV AAVrh10 IPL/mice Skaricic et al. (36)
SIV AAV1, scAAV1 IM/macaque Johnson et al. (37)
Influenza AAV8 IM/mice, ferrets Balazs et al. (38)
AAV9 IN/mice, ferrets,
macaques
Limberis et al. (39)
RSV, respiratory syncytial virus. See the legend ofTable 1 for additional abbrevi-
ations.
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2A self-processing peptide derived from the foot-and-mouth dis-
ease virus (FMDV2A) (40). With this technology, 1 mg/ml of Ab
was detected in the serum of the animals several months after
AAV administration, a level much superior to that previously
observed using an AAV2 vector expressing the two chains using
a dual promoter system (34). This initial report fostered a series
of studies to validate this strategy in various experimental models.
Notably, by using specific AAV serotypes, it was possible to address
Ab secretion into tissues such as the lungs, which are the site of
entry of several viruses and bacteria. For example, intra-pleural
administration of AAVrh10 encoding for a murine Ab against
the respiratory syncytial virus (RSV) resulted in the long-term
production of anti-RSV NAb in the serum and the lungs and par-
tially protected the animals against a challenge with the virus (36).
A similar strategy was developed to express in vivo Ab able to
protect against the deleterious effects induced by some toxins or
compounds such as anthrax, cocaine, or nicotine (41–43).
PROTECTION STUDIES AND PRE-CLINICAL EVALUATIONS
The use of AAV as vehicle for gene delivery to induce immune
responses against foreign and self-antigens has been explored in
animal models, but only one phase I clinical trial was performed
in humans (44). For prophylactic vaccination against infectious
agents, there are safety concerns since typically such vaccines are
given to healthy children or adolescents with an unknown risk for
late consequences. Also, prophylactic vaccines are often targeted to
large populations. From this standpoint, AAV vectors are interest-
ing tools since their use for gene therapy has already demonstrated
their overall absence of toxicity (6). However, current very high
costs for manufacturing AAV vectors and the need for high particle
doses are clearly major hurdles for vaccine development. Neverthe-
less, future studies may help define some niches in which AAV may
be particularly advantageous over other vaccination strategies.
This chapter will describe a number of informative pre-clinical
vaccination studies, which demonstrated a complete protection
against experimental challenge in a relevant animal model and/or
have explored the efficiency of AAV-mediated vaccination in NHP.
HENIPAVIRUSES
Nipah virus (NiV) and Hendra virus (HeV) are closely related,
recently emerged paramyxoviruses, belonging to the henipavirus
genus. Both viruses are capable of causing considerable morbid-
ity and mortality in a number of mammalian species, including
humans (45). Infection of humans is characterized by a rapid
and extensive spread of the virus in several organs with symp-
toms including respiratory distress and encephalitis (46). These
symptoms can be reproduced by experimental infection of sev-
eral animal models including hamsters (47). Because of their high
pathogenicity in humans, their broad tropism and the absence
of any vaccine or treatment, henipaviruses are presently classi-
fied as biosafety level 4 (BSL4) agents and considered as potential
biothreats (48).
The major vaccination strategy to prevent henipavirus infec-
tion has focused on direct administration of soluble forms of the
G viral glycoprotein to induce a protective immune response (49–
53). This form of vaccination requires several injections of the
recombinant protein coupled to adjuvants to achieve a significant
immune response. In a recent study, Ploquin et al. evaluated the
efficiency of AAV vectors expressing the NiV G protein to induce a
protective immune response (28). The evaluation of two routes of
vaccination and different prime/boost strategies employing three
AAV serotypes indicated that a single IM AAV injection in mice
was sufficient to induce a potent and long lasting Ab response con-
sisting of IgG and NAb. Further translational studies in hamsters
demonstrated that a single injection of an AAV vector encoding
NiV G was sufficient to protect 100% of the animals against a
lethal challenge with NiV and 50% of the animals against a chal-
lenge with HeV, thus indicating the induction of cross-neutralizing
immune responses. Altogether, this study presented a new vacci-
nation approach whereby a single immunization is sufficient for
the induction of a protective immunity against henipaviruses and
opened new perspectives toward the evaluation of AAV vectors as
a vaccine against these emergent infectious diseases.
HUMAN IMMUNODEFICIENCY VIRUS
Controlling the epidemic of HIV infection worldwide remains a
major challenge. Indeed, even though significant success in con-
trolling the disease has been achieved by understanding the virus
biology and by developing targeted drugs, vaccine-based preven-
tive measures are still needed. Major challenges toward this goal are
the antigenic variability and multitude of virus strains (54). Sev-
eral viral vectors have been tested as vaccines against HIV, most
notably poxviruses and Ad, but have met little success in protec-
tive efficacy and even adverse effects in terms of protection against
HIV infection (1). This was, in particular, the case of the STEP
human trial which used Ad vectors encoding HIV proteins (55).
Among several vaccine strategies, AAV vectors have been eval-
uated in several animal studies (Table 1). In an early study, an
AAV vector expressing the HIV env, tat, and rev genes was given to
BALB/c mice in single applications and by different administra-
tion routes including intramuscular and intra-nasal. This resulted
in the production of a high level of HIV-specific serum IgG and
fecal secretory IgA as well as in the appearance of a cytotoxic
T-cell response (15). Non-invasive oral administration of AAV2
vectors expressing the HIV env gene was further studied by Xin
and colleagues (16) who showed the induction of systemic and
mucosal humoral and cellular immune response that partially
protected against rectal challenge with a recombinant vaccinia
virus expressing the HIV env gene. The most advanced studies
in the field were conducted by Johnson et al. (22), who investi-
gated the efficacy of AAV2 vectors expressing several SIV genes
(rev-gag, rev-env, and RT-IN) injected intramuscularly against a
challenge with SIV (22). In this study, the authors demonstrated
the induction of robust T cell and Ab responses after a single
vaccination. Upon challenge with SIV, complete protection was
observed when low doses of SIV were given intravenously. How-
ever, only partial protection was observed at higher doses of SIV. Of
note, one phase I trial with AAV2 HIVgag-protease-∆RT demon-
strated safety but modest immunogenicity (Gag-specific T cells in
16% of the recipients) (44).
A much more interesting perspective in the field was pro-
vided by two recent studies which used AAV vectors for passive
immunotherapy (Table 2). This concept was first validated by
Johnson and colleagues, who used an AAV1 vector to express
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imunoadhesins (IA) against SIV in macaques (37). IA are chimeric
Ab-like molecules that are generally composed of the Fc region
of an immunoglobulin linked to the ligand-binding region of a
receptor or adhesion molecule. IA offer the advantage of being
small molecules whose sequence can be easily accommodated in
an AAV vector and eventually in a scAAV vector, which pack-
ages a double-stranded DNA genome enhancing the kinetics and
level of transgene expression (8). Johnson and colleagues demon-
strated that intra-muscular injection of the scAAV1 vector resulted
in a higher level of secretion of the IA than using a conven-
tional ss AAV1 and generated a long lasting neutralizing activity in
the serum. Importantly, most vaccinated animals were protected
against infection with SIV and all were protected against the dis-
ease. However, Ab against the IA were generated in some animals
and correlated with partial protection. The potential of AAV-
based passive immunotherapy against HIV infection was further
demonstrated by Balazs and colleagues, who reported the lifelong
expression in mice of monoclonal Ab against HIV after a single
intra-muscular injection of an AAV8 vector. Importantly, human-
ized mice vaccinated with AAV were protected against intravenous
injection of replication competent HIV at a very high dose (35).
HUMAN PAPILLOMAVIRUS
Two VLPs-based vaccines are commercially available against HPV
16 and HPV 18, which are the most important risk factors for
the development of cervical cancer and other malignant tumors
of the anogenital tract and of the head and neck. Clinical trials
and first reports after launching vaccination campaigns demon-
strated highly efficient protection against persistent infection and
precancerous lesions besides excellent safety profiles (56–58) [for
review, see Ref. (59)]. Early data on the influence of this vaccina-
tion strategy on cancer incidence are expected to arise 15–20 years
after initiation of mass immunization. Despite the high costs of the
available products, in the near future, an AAV-based HPV vaccine
is unlikely to become a serious contender to the existing vacci-
nation scheme, which involves three IM injections of adjuvanted
VLPs manufactured by recombinant expression of the HPV major
structural protein (L1). Yet, studies with HPV 16 L1 AAVs have
yielded interesting results in mice and NHP and make these vectors
an interesting option for future developments.
For example, Kuck and colleagues demonstrated a sustained
humoral and cellular immune response (>1 year) in mice immu-
nized with a single intra-nasal dose of AAV5-HPV16L1. The
responses by far outlasted the ones obtained after three doses of
HPV 16 VLPs that had been applied by the same route. Lyophilized
and re-dissolved AAV particles remained immunogenic albeit at
reduced efficiency (11). Thus, AAV has the potential for a needle-
less vaccine and – unlike the available vaccines – does not need
refrigeration since it can be stored as lyophilized powder. Both
features are important in developing countries where cervical
cancer is a major public health challenge. Intra-nasal immuniza-
tion with AAV9-HPV16L1 was also tested in NHP (macaques).
L1-specific NAb were elicited and persisted for at least 7 months
post AAV administration. As expected from previous studies, the
presence of pre-existing high titer AAV9 Ab did not prevent immu-
nization with the same serotype when administered intra-nasally
(14, 31).
As mentioned before, the introduction of prophylactic HPV
vaccination has the potential to significantly reduce the world-
wide burden of HPV-related disease. However, even in countries
with sufficient resources there will always be individuals that, for
reasons of ignorance about HPV as a human carcinogen or active
objection against vaccination per se, will not benefit from such
programs. Therefore, there is a medical need for the development
of HPV-specific therapeutic vaccines against an established infec-
tion. Such strategies involve cytotoxic T cells against early proteins
that are expressed in persistently infected and HPV-transformed
cells [for a review, see Ref. (60)]. One of the intensively studied
targets, namely the viral oncoprotein E7 has also been analyzed
as the transgene in AAV vectors (Table 1). Two studies used AAV
vectors coding for a 19 aa HPV 16 E7 peptide, which contains a
well-defined mouse (H-2b)-restricted CTL epitope or the com-
plete HPV 16 E7 gene fused to the Mycobacterium tuberculosis
heat shock protein 70 (hsp70) (9, 13). A single intra-muscular
immunization of C57/BL6 mice induced E7-specific CD4+ and
CD8+ T lymphocytes and – upon challenge with syngeneic E7-
transformed cells – a significant delay or a complete inhibition of
tumor growth. In experiments aiming toward an HPV 16 vaccine
that combines prophylactic and therapeutic properties, Nieto and
colleagues analyzed different AAV serotypes that carried a fusion
gene of L1 and the major part of E7 (12) by a single intra-nasal
immunization of mice. The AAV5 and the AAV9 (not the AAV8)
vectors efficiently induced both humoral and cellular immune
responses that were superior to vaccination with HPV16-L1 VLPs
or HPV16-L1/E7 chimeric VLPs. In addition, vaccination with the
AAV vectors led to a significant protection of animals against a
challenge with different HPV tumor cell lines.
INFLUENZA VIRUS
The currently available vaccines are insufficient to keep in check
the seasonal influenza outbreaks that affect people of all ages and
claim at least one millions of lives in children up to 5 years of age
worldwide (61). The reason vaccines are relatively less successful is
the high variability of the virus and highly type-specific nature of
the vaccines that need to be designed for the actual emerging virus
strain. The unavoidable delay between the identification of a new
variant and availability of the appropriate vaccine – particularly
owing to the laborious manufacturing process of virus replication
in chicken eggs – leaves the population unprotected at least against
the first wave of a new epidemic.
Earlier studies have demonstrated strain-specific immuniza-
tion and protection against lethal challenge. Sipo and col-
leagues generated AAV9 vectors expressing the hemagglutinin
(HA), nucleoprotein (NP), or matrix protein (M1) genes of the
A/Mexico/4603/2009 (H1N1) isolate, a pandemic influenza of
swine origin. After the single injection of a mixture of two or
three AAV serotypes, they obtained complete protection against
a homologous challenge and partial protection against a het-
erologous and highly virulent strain (25). The authors argued
that, although this vaccine candidate will not induce sterilizing
immunity it may mitigate the clinical symptoms, diminish the
transmission rate, and, thus, generate a herd immunity before
the homologous classical vaccines have been made available. A
slightly more recent study also examined the protection level in
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mice vaccinated with AAV vectors expressing NP. In particular, the
objective of those studies was to evaluate the efficacy of protec-
tion in mice receiving high doses of pooled human IgG to mimic a
situation in which a pre-existing immunity against AAV may inter-
fere with the vaccine. Interestingly in those studies, the authors
showed that an AAVrh32.33 vector-expressing NP could fully pro-
tect the animal against a challenge with lethal doses of influenza
virus strain PR8 (20). Altogether, these studies demonstrated the
efficiency of strain-specific AAV vaccines.
However, as for other RNA viruses, vaccination against seasonal
influenza outbreaks is complicated by the continuous emergence
of new variants or strains which escape NAb generated by the
previous infection. The recent isolation of cross-neutralizing Ab,
which bind to a conserved region of HA has recently allowed
the evaluation of new vaccination strategies based on passive
immunotherapy and aimed at generating a long-term broadly
protective humoral activity in vivo. Interestingly, two indepen-
dent groups simultaneously reported the use of AAV vectors to
produce, in vivo, either a full length human Ab against HA or an
IA directed against the same protein (38, 39). In the first study,
the authors injected the AAV8 vector intramuscularly in mice and
ferrets and demonstrated that the long-term production of the
anti-HA Ab in the serum conferred complete protection against
five different influenza strains (38). In the second study, an AAV9
vector was administered intranasally to induce production of the
IA in the nose and the lungs (39). An advantage of this mode of
delivery is that vector expression is localized to the nasal epithe-
lia and is not expected to be widely disseminated in the body.
In addition, the natural turnover of the airway epithelial cells
may ensure that the vector is not permanently present in vivo.
As in the first study, the animals were protected against the IN
challenge with different influenza strains. Importantly, in this lat-
ter example, the authors also showed that the time between AAV
injection and challenge could be reduced to 3 days, demonstrat-
ing the potency of this expression system (39). However, for both
studies, analyses performed in larger animal species, in partic-
ular ferrets, resulted in only partial or no protection probably
because of the emergence of an immune response against the
human Ab or the IA. Of course, an immune response against the
human Ab is not expected in humans. Whether the same holds
true for IA is still unclear. Even though some important issues,
such as the potential immunogenicity of IA and the translation
of this approach in larger animals still need improvements, these
approaches clearly indicate that AAV vectors are powerful tools for
passive immunotherapy which certainly deserve further studies in
NHP models.
CONCLUSION AND FUTURE DIRECTIONS
The studies conducted so far have highlighted several important
advantages of AAV vectors for vaccination and notably, in the case
of active immunotherapy, their capacity to induce sustained levels
of Ab responses after a single injection or in passive immunother-
apy, as tools for secreting Ab directly into the circulation. These
features are linked to the capacity of AAV vectors to persist for long
periods in the transduced tissues and clearly distinguish AAV from
other viral vectors, such as Ad and poxviruses, with which a rapid
elimination of transduced cells is observed in vivo. Despite these
properties, many drawbacks still hamper the use of these vectors as
a vaccine in humans. This last section will review the major prob-
lems, which remain to be solved and discuss possible solutions.
IMPROVING AAV IMMUNOGENICITY
The rationale for using AAV vectors for genetic vaccination is
mainly based on their intrinsic absence of pathogenicity, their
capacity to infect a variety of tissues, and to express transgenes
at a high and sustained level. When using AAVs for passive
immunotherapy, these properties are sufficient to consider AAV
vectors as very promising tools even though safety studies are
required to evaluate the effects of a continuous secretion of Ab
in vivo. However, in the case of active immunotherapy, these
properties may not always be sufficient to ensure an efficient vacci-
nation. Indeed, even if shown capable to induce transgene-specific
immune responses in large animal models (33) and to activate
innate responses at modest but detectable levels (62), AAV vec-
tors are still considered to possess a low immunogenic profile,
compared to other viral vectors, in particular Ad vectors. This
is notably illustrated by the persistence of transgene expression
observed in several vaccination studies and by the reported lack
of functional CD8+ T-cell responses observed with natural AAV
serotypes (19, 20, 28). This aspect clearly represents a major disad-
vantage for using AAVs for preventive or therapeutic vaccination
trials requiring the induction of robust cytotoxic T-cell responses.
Therefore, the use of these vectors for these applications requires
enhancement of their intrinsic immunogenic properties. Several
studies already indicate that this is possible, notably through the
manipulation of the viral genome and the capsid.
Increasing AAV immunogenicity by manipulating the vector
backbone
Adeno-associated virus vectors can be composed of a ss or a sc
DNA genome. Changing the nature of the DNA genome has a
profound impact on the kinetics and the level of transgene expres-
sion by bypassing the need for DNA second-strand synthesis before
transcription of the vector cassette (8). Accordingly, the compari-
son of ss and scAAV vectors for passive immunotherapy indicated
that the latter produced higher levels of Ab than the former (37).
Interestingly, several recent studies indicated that this modification
could also impact on the immunogenic properties of the vectors.
Indeed, modifying the vector backbone enhanced both innate and
transgene-specific adaptive immune responses (21, 63). In par-
ticular, using an AAV vector expressing a secreted version of the
HIV Gag protein, Wu and colleagues showed that scAAV vectors
of different serotypes induced more potent CD8+ T-cell and Ab
responses than conventional ssAAV (21). However, as previously
observed with conventional ssAAV vectors a progressive loss of
function of CD8+ T cell was observed, indicating that the mod-
ification of the nature of the vector genome was not sufficient to
generate fully functional T-cell responses. In addition, this strategy
was applicable only to transgenes that could be accommodated in
an expression cassette which was one half that of conventional
AAV vectors.
Increasing AAV immunogenicity by manipulating the capsid
Another strategy to enhance transgene-specific immune responses
induced by AAVs consists of changing the viral capsid. Obviously,
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the level and the nature of the immune response are tightly
linked to the nature of the capsids, which determines the tro-
pism of the particle and the efficiency of transduction. Accord-
ingly, several studies documented significant differences in the
levels of immune response induced by natural AAV serotypes
(12, 18, 19, 28). Presently, more than a 100 AAV variants have
been isolated from human and non-human tissues and approx-
imately 13 are used to produce vectors (29). An even greater
variety is offered by the possibility of genetically modifying the
capsid either by creating artificial variants or by inserting spe-
cific immunogenic peptides on the capsid surface as discussed
below (64).
Regarding the generation of new artificial AAV variants, the
most compelling evidence was provided by studies performed with
the AAVrh32.33. This variant is an engineered hybrid between
two natural AAV rhesus macaque isolates, which was specifi-
cally selected for its immunogenic properties. The analysis of the
immune response induced by this variant indicated that it was able
to induce a vibrant and functional CD8+ T-cell response directed
against the Ag, unlike the other natural AAV serotypes, and exploit-
ing this capacity was beneficial for vaccine development (20, 32).
The recent structural analysis of this variant further indicated that
the functional T-cell activating domain lies within the VP3 portion
of the capsid (65). A future deeper understanding of the immuno-
logical properties of the capsid domains of AAV may then lead
to the rational design of artificial variants capable of differentially
stimulating immune responses.
Other interesting strategies to increase AAV immunogenic-
ity have focused on the generation of capsid exposing selected
epitopes. AAV particles are composed of 60 capsid protein
subunits, named VP1, VP2, and VP3 (66). Efficient methods
to generate genetically modified capsid exposing selected pep-
tides have been developed in the recent years (67). Due to
the highly structured and repetitive presentation of epitopes
on the capsid, potent B-cell responses against this peptide are
expected. Two recent studies illustrate the feasibility of this
approach. Nieto and colleagues inserted two neutralizing epitopes
from the L2 protein of HPV16 and HPV31 into two different
positions of VP3 and used assembled empty AAV particles –
AAVLP(HPV16/31L2) – to vaccinate mice and rabbits. AAVLP
(HPV16/31L2) empty particles coupled to montanide adjuvant,
induced high levels of Ab able to cross neutralize several HPV
types (68). In a similar approach, Rybniker and colleagues used
genetically modified AAV2 capsids displaying at their surface
Ag85A, a well described Ag from M. tuberculosis. Using such mod-
ified capsids to package a vector over-expressing the same Ag,
increased the kinetics of Ab production as well as their avid-
ity, compared with an AAV assembled into a wild type capsid.
In addition, insertion of the antigen at the capsid surface was
also shown to be sufficient to induce a memory B-cell recall
response (27).
Both of these strategies illustrate the potential of capsid modifi-
cation for manipulating the immune response and it is likely that,
in a very near future, new AAV vectors specifically selected for their
ability to induce strong transgene-specific immune responses will
continue to emerge.
CIRCUMVENTING ANTI-AAV PRE-EXISTING IMMUNITY
Epidemiological studies indicate that anti-AAV Ab can be detected
in the majority of the population worldwide and that their
seroprevalence varies according to the AAV serotype and the geo-
graphical region (69–71) [for a review, see Ref. (72)]. As a result,
the efficacy of AAV vectors for in vivo gene transfer can be severely
reduced. In animal models, the use of an alternative AAV serotype
is sufficient to circumvent anti-AAV NAb induced by previous
immunization with a different capsid. However, this strategy may
not be valid in humans in which potentially wider cross-reacting
immune responses exist. Interestingly however, artificial variants
such as AAVrh32.33 showed a much lower seroprevalence than
natural serotypes, with less than 2% of the population testing
positive worldwide, indicating that it could represent a good can-
didate for vaccination (69). An additional strategy to circumvent
pre-existing immunity is provided by the possibility to engineer
AAV capsids with mutations targeting key immunogenic amino
acids. This sophisticated strategy was developed by Maersch and
colleagues, who demonstrated its feasibility by using the in vitro
directed evolution method to select AAV particles capable of
escaping anti-AAV2 NAb (73).
REDUCING AAV VECTOR DOSES
In gene therapy trials, the use of AAV vectors in humans requires
very high vector doses in order to achieve a therapeutic efficiency.
For example, doses of approximately 1012 vector particles per kilo-
gram were required in the initial Hemophilia B trials using AAV2
vectors (5). Even if lower doses were used in the latter trials using
other AAV serotypes, the amount of particles delivered as a single
injection in patients still remained impressively high. Experiments
performed in animals for vaccination with AAVs also used very
high doses to achieve an efficient immune response. Therefore, as
for gene therapy, application of high vector doses may constitute
a safety concern by increasing the risk of inducing detrimental
immune responses and of off-target transduction. Hence, future
efforts to reduce vector doses should focus on decreasing the vec-
tor load by improving transduction efficiencies and increasing the
immunogenicity of the vector particles.
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